Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 3, 2010, Pages 268-274

  Long, Millie D ^a   Herfarth, Hans H ^a   Pipkin, Clare A ^b   Porter, Carol Q ^c   Sandler, Robert S ^a   Kappelman, Michael D ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Anti TNF; Immunosuppression; Inflammatory Bowel Disease; Non Melanoma Skin Cancer; Thiopurines

Indexed keywords

ADALIMUMAB; CALCINEURIN INHIBITOR; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SKIN CANCER; ULCERATIVE COLITIS;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SKIN NEOPLASMS;

EID: 77349117814     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.11.024     Document Type: Article

References (27)

1. http://www.aad.org/media/background/factsheets/fact_skincancer.html Accessed October 20, 2009
2. Leiter U., and Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer: the role of sunlight. Adv Exp Med Biol 624 (2008) 89-103
3. Arora A., and Attwood J. Common skin cancers and their precursors. Surg Clin North Am 89 (2009) 703-712
4. Jensen P., Hansen S., Moller B., et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 40 (1999) 177-186
5. Lindelof B., Sigurgeirsson B., Gabel H., et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143 (2000) 513-519
6. Euvrard S., Kanitakis J., and Claudy A. Skin cancers after organ transplantation. N Engl J Med 348 (2003) 1681-1691
7. Mellemkjaer L., Olsen J.H., Frisch M., et al. Cancer in patients with ulcerative colitis. Int J Cancer 60 (1995) 330-333
8. Ekbom A., Helmick C., Zack M., et al. Extracolonic malignancies in inflammatory bowel disease. Cancer 67 (1991) 2015-2019
9. Bouhnik Y., Lemann M., Mary J.Y., et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347 (1996) 215-219
10. Kappelman M.D., Rifas-Shiman S.L., Kleinman K., et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 5 (2007) 1424-1429
11. Long M.D., Porter C.Q., Sandler R.S., et al. Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol 7 (2009) 549-553
12. Stempel D.A., Mauskopf J., McLaughlin T., et al. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 95 (2001) 227-234
13. Gupta G., Lautenbach E., and Lewis J.D. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4 (2006) 1483-1490
14. Housman T.S., Williford P.M., Feldman S.R., et al. Nonmelanoma skin cancer: an episode of care management approach. Dermatol Surg 29 (2003) 700-711
15. Rothman K.J., and Greenland S.E. Modern epidemiology (1998), Lippincott Williams and Wilkins, Philadelphia 124-125
16. Berg D., and Otley C.C. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 47 (2002) 1-17 quiz 18-20
17. Webb M.C., Compton F., Andrews P.A., et al. Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc 29 (1997) 828-830
18. Ramsay H.M., Fryer A.A., Hawley C.M., et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 147 (2002) 950-956
19. Esser A.C., Abril A., Fayne S., et al. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 50 (2004) S75-S77
20. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
21. Chakravarty E.F., Michaud K., and Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 32 (2005) 2130-2135
22. Caspersen S., Elkjaer M., Riis L., et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 6 (2008) 1212-1217 quiz 1176
23. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58 (2009) 501-508
24. O'Donovan P., Perrett C.M., Zhang X., et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309 (2005) 1871-1874
25. Parrish J.A. Immunosuppression, skin cancer, and ultraviolet A radiation. N Engl J Med 353 (2005) 2712-2713
26. Herrinton L.J., Liu L., Lafata J.E., et al. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis 13 (2007) 451-461
27. Flasar M.H., Johnson T., Roghmann M.C., et al. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis 14 (2008) 13-19